Hostname: page-component-848d4c4894-ttngx Total loading time: 0 Render date: 2024-05-05T04:17:28.931Z Has data issue: false hasContentIssue false
  • English
  • Français

Serum endocan levels in children with rheumatic aortic insufficiency: can it differentiate bicuspid aortic valve disease from rheumatic heart disease?

Published online by Cambridge University Press:  14 September 2022

Fuat Laloğlu Open the ORCID record for Fuat Laloğlu [Opens in a new window] ,
Esra Laloğlu Open the ORCID record for Esra Laloğlu [Opens in a new window] ,
Naci Ceviz Open the ORCID record for Naci Ceviz [Opens in a new window]  and
Muhammet Akif Güler Open the ORCID record for Muhammet Akif Güler [Opens in a new window]
Fuat Laloğlu*
Affiliation:
Department of Pediatrics, Division of Pediatric Cardiology, Ataturk University Faculty of Medicine, Erzurum, Turkey
Esra Laloğlu
Affiliation:
Department of Medical Biochemistry, Ataturk University Faculty of Medicine, Erzurum, Turkey
Naci Ceviz
Affiliation:
Department of Pediatrics, Division of Pediatric Cardiology, Ataturk University Faculty of Medicine, Erzurum, Turkey
Muhammet Akif Güler
Affiliation:
Department of Pediatrics, Division of Pediatric Nephrology, Ataturk University Faculty of Medicine, Erzurum, Turkey
*
Author for correspondence: Fuat Laloğlu, Department of Pediatrics, Division of Pediatric Cardiology, Ataturk University Faculty of Medicine, 25100, Erzurum, Turkey. Tel: + 90 (442) 344 7885; Fax: +90 (442) 236 09 68. E-mail: flaloglu25@hotmail.com
Get access Rights & Permissions [Opens in a new window]

Abstract

Aim:

In this study, it was aimed to examine the serum endocan levels in patients with rheumatic aortic regurgitation and to investigate whether it has a value in differentiating it from aortic regurgitation due to bicuspid aortic valve.

Methods:

Blood samples were collected from patients with rheumatic aortic regurgitation (Group 1), incidentally diagnosed patients with borderline or definite rheumatic aortic regurgitation (Group 2), children with bicuspid aortic valve accompanied by aortic regurgitation (Group 3) and healthy children (Group 4) of similar age.

Results:

There were 12 children in Group 1, 13 in Group 2, 25 in Group 3, and 25 in Group 4. Groups were similar in terms of age (p = 0.291). There was no statistically significant difference between median serum endocan levels of Group 1 and Group 2 (p = 0.624), and Group 3 and Group 4 (p = 0.443). Despite that, the median serum endocan levels of Group 1 and Group 2 were significantly higher than that of both Group 3 and Group 4 (p = 0.000 for all).

Conclusions:

Our results indicate that serum endocan level can be used to differentiate rheumatic aortic regurgitation from non-rheumatic aortic regurgitation. It is thought that the prognostic role of this marker should be confirmed in long-term, prospective studies with larger samples.

Keywords

Endocanaortic insufficiencyrheumatic heart diseasebicuspid aortic valve
Type
Original Article
Information
Cardiology in the Young , Volume 33 , Issue 8 , August 2023 , pp. 1396 - 1400
Check for updates
Copyright
© The Author(s), 2022. Published by Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Carapetis, JR, Steer, AC, Mulholland, EK, Weber, M. The global burden of group A streptococcal diseases. Lancet Infect Dis 2005; 5: 685–694.CrossRefGoogle Scholar
Gewitz, MH, Baltimore, RS, Tani, LY, et al. Revision of the Jones Criteria for the diagnosis of acute rheumatic fever in the era of Doppler echocardiography: a scientific statement from the American Heart Association. Circulation 2015; 131: 1806–1818.CrossRefGoogle Scholar
Dajani, AS, Ayoub, E, Bierman, FZ, et al. Guidelines for the diagnosis of rheumatic fever: Jones Criteria, 1992 update. JAMA 1992; 268: 2069–2073.CrossRefGoogle Scholar
Guilherme, L, Kalil, J, Cunningham, M. Molecular mimicry in the autoimmune pathogenesis of rheumatic heart disease. Autoimmunity 2006; 39: 31–39.CrossRefGoogle ScholarPubMed
Carapetis, JR, Beaton, A, Cunningham, MW, et al. Acute rheumatic fever and rheumatic heart disease. Nat Rev Dis Prim 2016; 2: 15084.CrossRefGoogle ScholarPubMed
Galvin, JE, Hemric, ME, Ward, K, Cunningham, MW. Cytotoxic mAb from rheumatic carditis recognizes heart valves and laminin. J Clin Invest 2000; 106: 217–224.CrossRefGoogle ScholarPubMed
Guilherme, L, Dulphy, N, Douay, C, et al. Molecular evidence for antigen-driven immune responses in cardiac lesions of rheumatic heart disease patients. Int Immunol 2000; 12: 1063–1074.CrossRefGoogle ScholarPubMed
Cunningham, MW, Antone, SM, Smart, M, Liu, R, Kosanke, S. Molecular analysis of human cardiac myosin-cross-reactive B- and T-cell epitopes of the group A streptococcal M5 protein. Infect Immun 1997; 65: 3913–3923.CrossRefGoogle Scholar
Reméanyi, B, Wilson, N, Steer, A, et al. World Heart Federation criteria for echocardiographic diagnosis of rheumatic heart disease--an evidence-based guideline. Nat Rev Cardiol 2012; 9: 297–309.CrossRefGoogle Scholar
Ralph, AP, Noonan, S, Wade, V, Currie, BJ. The 2020 Australian guideline for prevention, diagnosis and management of acute rheumatic fever and rheumatic heart disease. Med J Aust 2021; 214: 220–227.CrossRefGoogle ScholarPubMed
Roudnicky, F, Poyet, C, Wild, P, et al. Endocan is upregulated on tumor vessels in invasive bladder cancer where it mediates VEGF-A-induced angiogenesis. Cancer Res 2013; 73: 1097–1106.CrossRefGoogle ScholarPubMed
Vos, T, Barber, RM, Bell, B, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015; 386: 743–800.CrossRefGoogle Scholar
Guilherme, L, Ramasawmy, R, Kalil, J. Rheumatic fever and rheumatic heart disease: genetics and pathogenesis. Scand J Immunol 2007; 66: 199–207.CrossRefGoogle ScholarPubMed
Markowitz, M. Clinical manifestations of acute rheumatic fever. In: Markowitz, M, Gordis, L (eds). Rheumatic Fever. W.B. Saunders, Philadelphia, 1972: 62–70.Google ScholarPubMed
Persellin, RH. Acute rheumatic fever: changing manifestations. Ann Intern Med 1978; 89: 1002–1003.CrossRefGoogle ScholarPubMed
Liu, M, Lu, L, Sun, RR, Zheng, Y, Zhang, P. Rheumatic heart disease: causes, symptoms, and treatments. Cell Biochem Biophys 2015; 72: 861–863.CrossRefGoogle ScholarPubMed
Saphir, O. The Aschoff nodule. Am J Clin Pathol 1959; 31: 534–539.CrossRefGoogle ScholarPubMed
Câmara, EJN, Neubauer, C, Câmara, GF, Lopes, AA. Mechanisms of mitral valvar insufficiency in children and adolescents with severe rheumatic heart disease: an echocardiographic study with clinical and epidemiological correlations. Cardiol Young 2004; 14: 527–532.CrossRefGoogle ScholarPubMed
Kamblock, J, N’Guyen, L, Pagis, B, et al. Acute severe mitral regurgitation during first attacks of rheumatic fever: clinical spectrum, mechanisms and prognostic factors. J Heart Valve Dis 2005; 14: 440–446.Google ScholarPubMed
Shulman, ST, Ayoub, EM, Victorica, BE, Gessner, IH, Tamer, DF, Hernandez, FA. Differences in antibody response to streptococcal antigens in children with rheumatic and non-rheumatic mitral valve disease. Circulation 1974; 50: 1244–1251.CrossRefGoogle ScholarPubMed
Appleton, RS, Victorica, BE, Tamer, D, Ayoub, EM. Specificity of persistence of antibody to the streptococcal group A carbohydrate in rheumatic valvular heart disease. J Lab Clin Med 1985; 105: 114–119.Google Scholar
Dudding, BA, Ayoub, EM. Persistence of streptococcal group A antibody in patients with rheumatic valvular disease. J Exp Med 1968; 128: 1081–1098.CrossRefGoogle Scholar
Oakes, SA. Inflammation and repair. In: Kumar, V, Abbas, AK, Aster, JC (eds). Robbins & Cotran Pathologic Basis of Disease. Elsevier, Canada, 2021: 105–110.Google Scholar
Carmeliet, P. Angiogenesis in health and disease. Nat Med 2003; 9: 653–660.CrossRefGoogle ScholarPubMed
Conway, EM, Collen, D, Carmeliet, P. Molecular mechanisms of blood vessel growth. Cardiovasc Res 2001; 49: 507–521.CrossRefGoogle ScholarPubMed
Mitchell, RN. The cell as a unit of health and disease. In: Kumar, V, Abbas, AK, Aster, JC (eds). Robbins & Cotran Pathologic Basis of Disease. Elsevier, Canada, 2021: 20–25.Google Scholar
Sarrazin, S, Adam, E, Lyon, M, et al. Endocan or endothelial cell specific molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy. Biochim Biophys Acta 2006; 1765: 25–37.Google ScholarPubMed
Lee, HG, Choi, HY, Bae, JS. Endocan as a potential diagnostic or prognostic biomarker for chronic kidney disease. Kidney Int 2014; 86: 1079–1081.CrossRefGoogle ScholarPubMed
Gerszten, RE, Garcia-Zepeda, EA, Lim, YC, et al. MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature 1999; 398: 718–725.CrossRefGoogle ScholarPubMed
Balta, S, Mikhailidis, DP, Demirkol, S, Ozturk, C, Celik, T, Iyisoy, A. Endocan: a novel inflammatory indicator in cardiovascular disease? Atherosclerosis 2015; 243: 339–343.CrossRefGoogle ScholarPubMed
Oktar, SF, Guney, I, Eren, SA, et al. Serum endocan levels, carotid intima-media thickness and microalbuminuria in patients with newly diagnosed hypertension. Clin Exp Hypertens 2019; 41: 787–794.CrossRefGoogle ScholarPubMed
Béchard, D, Scherpereel, A, Hammad, H, et al. Human endothelial-cell specific molecule-1 binds directly to the integrin CD11a/CD18 (LFA-1) and blocks binding to intercellular adhesion molecule-1. J Immunol 2001; 167: 3099–3106.CrossRefGoogle Scholar
Abu El-Asrar, AM, Nawaz, MI, De Hertogh, G, et al. The angiogenic biomarker endocan is upregulated in proliferative diabetic retinopathy and correlates with vascular endothelial growth factor. Curr Eye Res 2015; 40: 321–331.CrossRefGoogle ScholarPubMed
Icli, A, Cure, E, Cure, MC, et al. Endocan levels and subclinical atherosclerosis in patients with systemic lupus erythematosus. Angiology 2016; 67: 749–755.CrossRefGoogle ScholarPubMed
Wang, XS, Yang, W, Luo, T, Wang, JM, Jing, YY. Serum endocan levels are correlated with the presence and severity of coronary artery disease in patients with hypertension. Genet Test Mol Biomarkers 2015; 19: 124–127.CrossRefGoogle ScholarPubMed
Kali, A, Rathan Shetty, KS. Endocan: a novel circulating proteoglycan. Indian J Pharmacol 2014; 46: 579–583.CrossRefGoogle ScholarPubMed
Strasser, GA, Kaminker, JS, Tessier-Lavigne, M. Microarray analysis of retinal endothelial tip cells identifies CXCR4 as a mediator of tip cell morphology and branching. Blood 2010; 115: 5102–5110.CrossRefGoogle ScholarPubMed
Del Toro, R, Prahst, C, Mathivet, T, et al. Identification and functional analysis of endothelial tip cell-enriched genes. Blood 2010; 116: 4025–4033.CrossRefGoogle ScholarPubMed
Abid, MR, Yi, X, Yano, K, Shih, SC, Aird, WC. Vascular endocan is preferentially expressed in tumor endothelium. Microvasc Res 2006; 72: 136–145.CrossRefGoogle ScholarPubMed
Grigoriu, BD, Depontieu, F, Scherpereel, A, et al. Endocan expression and relationship with survival in human non-small cell lung cancer. Clin Cancer Res 2006; 12: 4575–4582.CrossRefGoogle ScholarPubMed
Béchard, D, Gentina, T, Delehedde, M, et al. Endocan is a novel chondroitin sulfate/dermatan sulfate proteoglycan that promotes hepatocyte growth factor/scatter factor mitogenic activity. J Biol Chem 2001; 276: 48341–48349.CrossRefGoogle ScholarPubMed
Klisic, A, Kavaric, N, Abenavoli, L, et al. Is endocan a novel potential biomarker of liver steatosis and fibrosis? J Med Biochem 2020; 39: 363–371.Google ScholarPubMed
Bălănescu, P, Lădaru, A, Bălănescu, E, Voiosu, T, Băicuş, C, Dan, GA. Endocan, novel potential biomarker for systemic sclerosis: results of a pilot study. J Clin Lab Anal 2016; 30: 368–373.CrossRefGoogle ScholarPubMed
Lo, Gullo A, Mandraffino, G, Rodríguez-Carrio, J, et al. Endocan and circulating progenitor cells in women with systemic sclerosis: association with inflammation and pulmonary hypertension. Biomedicines 2021; 9: 533.Google Scholar
Liakouli, V, Cipriani, P, Di Benedetto, P, et al. The role of extracellular matrix components in angiogenesis and fibrosis: possible implication for systemic sclerosis. Mod Rheumatol 2018; 28: 922–932.CrossRefGoogle ScholarPubMed
Cayci, FS, Aydin, Z, Aygar, IS, et al. Endocan levels in children with renal hypodysplasia. Clin Nephrol 2021; 95: 332–338.CrossRefGoogle ScholarPubMed